You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,567,422


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,567,422
Title: Azlactone activated polyalkylene oxides conjugated to biologically active nucleophiles
Abstract:Water-soluble azlactone activated polyalkylene oxides having improved hydrolytic stability and conjugates of the azlactone activated polyalkylene oxides with biologically active nucleophiles are disclosed. Methods of forming and conjugating the activated polyalkylene oxides with biologically active nucleophiles are also disclosed.
Inventor(s): Greenwald; Richard B. (Somerset, NJ)
Assignee: Enzon, Inc. (Piscataway, NJ)
Application Number:08/220,307
Patent Claims:1. A polyalkylene oxide conjugate comprising:

a nucleophile having biological activity; and

at least one water-soluble polyalkylene oxide covalently bonded thereto by a hydrolytically stable linkage formed by reacting said nucleophile with an azlactone-activated polyalkylene oxide comprising a structure represented by: ##STR9## wherein: R represents the non-terminal portion of a water-soluble polyalkylene oxide having a number average molecular weight between about 600 and about 100,000 daltons;

L is selected from the group consisting of --O-- and --CH.sub.2 --;

R.sub.1 is a moiety selected from the group consisting of hydrogen, alkyl and cycloalkyl moieties; carbocyclic and heterocyclic aromatic rings and .alpha.,.beta.-unsaturated alkyl moieties;

R.sub.4 and R.sub.5 are moieties independently selected from the group consisting of hydrogen, alkyl, aryl and alkylaryl moieties; and

X is a terminal moiety of said polyalkylene oxide selected from the group consisting of alkoxy moieties containing up to four carbon atoms.

2. The polyalkylene oxide conjugate of claim 1, wherein said polyalkylene oxide is selected from the group consisting of polyethylene glycol and block copolymers of polyethylene glycol and polypropylene glycol.

3. The polyalkylene oxide conjugate of claim 1, wherein said polyalkylene oxide has a number average molecular weight between about 2,000 and about 20,000 daltons.

4. The polyalkylene oxide conjugate of claim 3, wherein said polyalkylene oxide has a 5,000 dalton number average molecular weight.

5. The polyalkylene oxide conjugate of claim 1, wherein said azlactone activated polyalkylene oxide comprises an unsaturated azlactone ring.

6. The polyalkylene oxide conjugate of claim 1, wherein said azlactone activated polyalkylene oxide comprises a saturated azlactone ring.

7. The polyalkylene oxide conjugate of claim 1, wherein said nucleophile having biological activity is selected from the group consisting of enzymes, proteins, antibodies, antibody fragments, single chain antigens, nucleotides, oligonucleotides, immunoglobulins, and chemotherapeutic molecules having an appropriately reactive nucleophillic moiety.

8. The polyalklene oxide conjugate of claim 7, wherein said enzyme is selected from the group consisting of oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases.

9. The polyalklene oxide conjugate of claim 7, wherein said enzyme is selected from the group consisting of asparaginase, arginase, adenosine deaminase, superoxide dismutase, catalase, chymotrypsin, lipase, uricase, bilirubin oxidase, glucose oxidase, glucosidase, galactosidase, glucocerebrosidase and glucuronidase.

10. The polyalklene oxide conjugate of claim 7, wherein said protein is selected from the group consisting of hemoglobin, serum proteins, Factor VIII, Factor IX, immunoglobulins, lectins, interleukins, interferons, colony stimulating factors, ovalbumin, bovine serum albumin (BSA) hormones, insulin, ACTH, glucagon, somatostatin, somatotropins, thymosin, parathyroid hormone, pigmentary hormones, somatomedins, erythropoietin, luteinizing hormone, hypothamic releasing factors, antidiuretic hormones, prolactin, chorionic gonadotropin, follicle-stimulating hormone, thyroid-stimulating hormone, and tissue plasminogen activator.

11. The polyalklene oxide conjugate of claim 7, wherein said immunoglobulin is selected from the group cosisting of IgG, IgE, IgM, IgA, IgD and fragments thereof.

Details for Patent 5,567,422

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 01/15/1974 ⤷  Try a Trial 2013-10-22
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 12/27/1984 ⤷  Try a Trial 2013-10-22
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 02/15/1985 ⤷  Try a Trial 2013-10-22
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 02/16/1990 ⤷  Try a Trial 2013-10-22
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 03/26/1974 ⤷  Try a Trial 2013-10-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.